Join to View Full Profile
1515 Holcombe AvenueHouston, TX 77030
Phone+1 832-748-6369
Dr. Ye is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015- Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2009 - 2012
Wayne State University School of MedicineResidency, Internal Medicine, 2009 - 2012
Shanghai Jiao Tong University School of MedicineClass of 1993
Certifications & Licensure
TX State Medical License 2022 - 2027
MI State Medical License 2009 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsSafety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique C Minnema, Jesus G Berdeja
The Lancet. Haematology. 2025-04-01 - Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy.Gohar S Manzar, Stephanie O Dudzinski, Alison K Yoder, Aaron Seo, Lewis F Nasr
Clinical Lymphoma, Myeloma & Leukemia. 2025-04-01 - 2 citationsInternational myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal
Leukemia. 2025-03-01
Abstracts/Posters
- Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma„Alone or in Combination with RituximabJ Christine Ye, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...J Christine Ye, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Associate
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
